Last $49.99 USD
Change Today +1.26 / 2.59%
Volume 352.7K
ANIK On Other Exchanges
Symbol
Exchange
NASDAQ GS
Frankfurt
As of 8:10 PM 07/11/14 All times are local (Market data is delayed by at least 15 minutes).

anika therapeutics inc (ANIK) Snapshot

Open
$48.70
Previous Close
$48.73
Day High
$50.89
Day Low
$47.81
52 Week High
02/26/14 - $52.49
52 Week Low
07/19/13 - $18.70
Market Cap
720.9M
Average Volume 10 Days
316.3K
EPS TTM
$2.13
Shares Outstanding
14.4M
EX-Date
--
P/E TM
23.4x
Dividend
--
Dividend Yield
--
Current Stock Chart for ANIKA THERAPEUTICS INC (ANIK)

Related News

No related news articles were found.

anika therapeutics inc (ANIK) Related Businessweek News

No Related Businessweek News Found

anika therapeutics inc (ANIK) Details

Anika Therapeutics, Inc., together with its subsidiaries, develops, manufactures, and commercializes therapeutic products for tissue protection, healing, and repair in the United States, Europe, and internationally. The company’s products are based on hyaluronic acid (HA), a naturally occurring biocompatible polymer found in the body. Its orthobiologics products comprise ORTHOVISC, ORTHOVISC mini, and MONOVISC for the treatment of osteoarthritis of the knee and joints; Hyalofast, a biodegradable support for human bone marrow mesenchymal stem cells that is used in connection with soft tissue regeneration; Hyalonect, a woven gauze used as a graft wrap; Hyaloss used to mix blood/bone grafts to form a paste for bone regeneration; and Hyaloglide, an ACP gel used in tenolysis treatment. The company’s dermal products include wound care products that comprise Hyalomatrix and Hyalofill, for treatment of complex wounds, such as burns and ulcers; Hyalograft 3D and Laserskin scaffolds for use in connection with the regeneration of skin; and ELEVESS, an aesthetic dermatology product. Its surgical products comprise Hyalobarrier, a post-operative adhesion barrier for use in the abdomino-pelvic area; INCERT, a HA product for the prevention of spinal post-surgical adhesions; Merogel, a woven fleece nasal packin; and Merogel Injectable, a viscous hydrogel. The company’s ophthalmic products include AMVISC, AMVISC Plus, STAARVISC-II, Optivisc, AnikaVisc, and AnikaVisc Plus that are injectable HA products used as viscoelastic agents in ophthalmic surgical procedures, including cataract extraction and intraocular lens implantation; and veterinary product comprise HYVISC, an injectable HA product used for the treatment of joint dysfunction in horses. Anika Therapeutics, Inc. markets its products through a network of distributors. The company was founded in 1983 and is headquartered in Bedford, Massachusetts.

102 Employees
Last Reported Date: 03/13/14
Founded in 1983

anika therapeutics inc (ANIK) Top Compensated Officers

Chief Executive Officer, President and Direct...
Total Annual Compensation: $1.1M
Chief Financial Officer, Principal Accounting...
Total Annual Compensation: $400.9K
Chief Commercial Officer
Total Annual Compensation: $452.8K
Chief Scientific Officer
Total Annual Compensation: $116.7K
Compensation as of Fiscal Year 2013.

anika therapeutics inc (ANIK) Key Developments

Anika Therapeutics Inc. Provides Earnings Guidance for the 2014

Anika Therapeutics Inc. provided earnings guidance for the 2014. For the year the company expects to achieve product revenue growth for the year in the low 20% range, with at least equivalent net income and EPS growth for the year. This expectation is excluding milestone revenue and weighted to the third and fourth quarter.

Anika Therapeutics Inc. Announces Consolidated Unaudited Earnings Results for the First Quarter Ended March 31, 2014

Anika Therapeutics Inc. announced consolidated unaudited earnings results for the first quarter ended March 31, 2014. For the quarter, the company reported total revenues of $34,010,287 compared with $15,247,011 for the same period a year ago. Income from operations was $23,870,568 compared with $5,011,424 for the same period a year ago. Income before income taxes was $23,871,035 compared with $4,971,866 for the same period a year ago. Net income was $15,030,253 or $0.97 per diluted share compared with $3,068,002 or $0.21 per diluted share for the same period a year ago. Operating income, net income and earnings per share were higher year-over-year, primarily due to operating leverage on its sales volume and the milestone and contract revenue related to Monovisc(R) in the U.S. First-quarter 2014 total revenue included $19.7 million in milestone and contract revenue associated with Anika's U.S. license agreement for Monovisc(R), as the development obligations under the agreement were fully delivered prior to the end of the quarter. This primarily consisted of a milestone payment related to the product approval and successful resolution of patent litigation. Revenue for the first quarter of 2014 also included an initial U.S. stocking order for Monovisc(R) in preparation for the product's U.S. commercial launch. Anika's product revenue for the first quarter of 2014 was $14.4 million, at a level similar to the first quarter last year and consistent with its expectation. Product revenue in the first quarter of 2014 reflected order timing by its major distributors and is not indicative of product revenue growth rates in subsequent quarters of 2014.

Anika Therapeutics Inc., Annual General Meeting, Jun 05, 2014

Anika Therapeutics Inc., Annual General Meeting, Jun 05, 2014., at 11:30 Eastern Daylight. Location: 32 Wiggins Avenue,. Agenda: To elect two Class III directors nominated by the board of directors, each to serve until the 2017 annual meeting of stockholders and until their respective successors are duly elected and qualified; to ratify the appointment of PricewaterhouseCoopers LLP as the company's independent registered public accounting firm for the 2014 fiscal year; to consider and approve an advisory vote regarding the compensation of the company's named executive officers; and to consider and act upon any other matters that may properly come before the annual meeting or any adjournment or postponement thereof.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
ANIK:US $49.99 USD +1.26

ANIK Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Iridex Corp $7.97 USD +0.04
STAAR Surgical Co $12.67 USD +0.39
View Industry Companies
 

Industry Analysis

ANIK

Industry Average

Valuation ANIK Industry Range
Price/Earnings 22.6x
Price/Sales 7.5x
Price/Book 4.6x
Price/Cash Flow 21.6x
TEV/Sales 6.6x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact ANIKA THERAPEUTICS INC, please visit www.anikatherapeutics.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.